-
A case of familial donor-derived acute myeloid leukemia with underlying pre-leukemic mutations. Haematologica (IF 10.1) Pub Date : 2024-05-09 Luca Vincenzo Cappelli, Clara Minotti, Manja Meggendorfer, Marietta Truger, Torsten Haferlach, Cristina Mecucci, Caterina Matteucci, Caterina Alati, Anna Paola Iori, Maurizio Martelli, Robin Foà
Not available.
-
The diversity of the microbiome impacts chronic lymphocytic leukemia development in mice and humans. Haematologica (IF 10.1) Pub Date : 2024-05-09 Tereza Faitova, Mariana Coelho, Caspar Da Cunha-Bang, Selcen Ozturk, Ece Kartal, Peer Bork, Martina Seiffert, Carsten U Niemann
The gut microbiota play a critical role in maintaining a healthy human body and their dysregulation is associated with various diseases. In this study, we investigated the influence of the gut microbiome diversity on chronic lymphocytic leukemia (CLL) development. Stool sample analysis of 59 CLL patients revealed individual and heterogeneous microbiome compositions, but allowed for grouping of patients
-
HES6: an emerging player in human hematopoiesis. Haematologica (IF 10.1) Pub Date : 2024-05-09 Jian Xu, Wei Du
Not available.
-
Management of hyperleukocytosis in pediatric acute myeloid leukemia using immediate chemotherapy without leukapheresis: results from the NOPHO-DBH AML 2012 Protocol. Haematologica (IF 10.1) Pub Date : 2024-05-09 Bernward Zeller, Nira Arad-Cohen, Daniel Cheuk, Barbara De Moerloose, Jose M Fernandez Navarro, Henrik Hasle, Kirsi Jahnukainen, Kristian Lovvik Juul-Dam, Gertjan Kaspers, Zanna Kovalova, Olafur G Jonsson, Birgitte Lausen, Monica Munthe-Kaas, Ulrika Noren Nystrom, Josefine Palle, Ramune Pasauliene, Cornelis J Pronk, Kadri Saks, Anne Tierens, Jonas Abrahamsson
Hyperleukocytosis (HL) in pediatric acute myeloid leukemia (AML) is associated with severe complications and inferior outcome. We report results on HL patients included in the NOPHO-DBH AML 2012 study. We recommended immediate start of full dose chemotherapy (etoposide [ETO] monotherapy for 5 days as part of the first course), avoiding leukapheresis (LA) and prephase chemotherapy (PCT). Of 714 included
-
The insertion/deletion polymorphism rs201494641 at ITGA9 influences blood CD34+ cell levels by altering ZNF384 binding. Haematologica (IF 10.1) Pub Date : 2024-05-09 Caterina Cafaro, Zain Ali, Antton Lamarca, Daniela Torres Di Bello, Laura Duran Lozano, Ludvig Ekdahl, Malte Thodberg, Maroulio Pertesi, Aitzkoa Lopez De Lapuente Portilla, Björn Nilsson
Not available.
-
Anti-T-lymphocyte globulin exposure is associated with acute graft-versus-host disease and relapse in pediatric acute lymphoblastic leukemia patients undergoing hematopoietic stem cell transplantation: a multinational prospective study. Haematologica (IF 10.1) Pub Date : 2024-05-09 Lisa V E Oostenbrink, Erik G J Von Asmuth, Cornelia M Jol-van der Zijde, Anja M Jansen-Hoogendijk, Carly Vervat, Robbert G M Bredius, Maarten J D Van Tol, Marco W Schilham, Petr Sedlacek, Marianne Ifversen, Adriana Balduzzi, Peter Bader, Christina Peters, Dirk Jan A R Moes, Arjan C Lankester
Anti T-lymphocyte globulin (ATLG) is used in hematopoietic stem cell transplantation (HSCT) to prevent graft-versus-host disease (GvHD) and graft failure. To date, insight in ATLG pharmacokinetics and -dynamics (PK/PD) is limited, and population PK (POPPK) models are lacking. In this prospective study, we describe ATLG POPPK using NONMEM® and the impact of ATLG exposure on clinical outcome and immune
-
Cachexia during anti-leukemia chemotherapy: it is not "just" the chemo. Haematologica (IF 10.1) Pub Date : 2024-05-09 Armin Rashidi
Not available.
-
From niche to blockbuster: a greater role for allopurinol in maintenance treatment of acute lymphoblastic leukemia. Haematologica (IF 10.1) Pub Date : 2024-05-09 Martin Stanulla
Not available.
-
Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy. Haematologica (IF 10.1) Pub Date : 2024-05-09 Chiara Tarantelli, David Wald, Nicolas Munz, Filippo Spriano, Alessio Bruscaggin, Eleonora Cannas, Luciano Cascione, Eugenio Gaudio, Alberto J Arribas, Shivaprasad Manjappa, Gaetanina Golino, Lorenzo Scalise, Maria Teresa Cacciapuoti, Emanuele Zucca, Anastasios Stathis, Giorgio Inghirami, Patrick H Van Berkel, Davide Rossi, Paolo F Caimi, Francesca Zammarchi, Francesco Bertoni
Antibody-drug conjugates (ADCs) represent one of the most successful therapeutic approaches introduced in clinical practice in the last few years. Loncastuximab tesirine (ADCT-402) is a CD19 targeting ADC, in which the antibody is conjugated through a protease cleavable dipeptide linker to a pyrrolobenzodiazepine (PBD) dimer warhead (SG3199). Based on the results of a phase 2 study, loncastuximab tesirine
-
Mental health and use of psychotropic prescription drugs in adult patients with primary immune thrombocytopenia: a nationwide population-based cohort study. Haematologica (IF 10.1) Pub Date : 2024-05-09 Nikolaj Mannering, Dennis Lund Hansen, Anton Pottegård, Kjeld Andersen, Henrik Frederiksen
Patients with primary immune thrombocytopenia (ITP) suffer from reduced survival and quality of life, but the underlying reasons for this are largely undescribed. Mental health and the use of psychotropic drugs in ITP is unknown. We investigated the risk of hospital registered mental health events including fatigue and the use of psychotropic drugs in adult patients with ITP compared with the general
-
Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors. Haematologica (IF 10.1) Pub Date : 2024-05-09 Yoshiko Atsuta, Helen Baldomero, Daniel Neumann, Anna Sureda, Jakob D DeVos, Minako Iida, Amado Karduss, Duncan Purtill, Alaa M Elhaddad, Nosa G Bazuaye, Carmem Bonfim, Rafael De la Camara, Naeem A Chaudhri, Fabio Ciceri, Cinthya Correa, Cristobal Frutos, Sebastian Galeano, Laurent Garderet, Oscar Gonzalez-Ramella, Raffaella Greco, Nada Hamad, Mette D Hazenberg, Mary M Horowitz, Krzysztof Kalwak, Bor-Sheng
Promoting access to and excellence in hematopoietic cell transplantation (HCT) by collecting and disseminating data on global HCT activities is one of the principal activities of the Worldwide Network for Blood and Marrow Transplantation, a non-Governmental organization in working relations with the World Health Organization. HCT activities are recorded annually by member societies, national registries
-
A rescue approach in refractory diffuse large B-cell lymphoma with obinutuzumab-redirected cytokine-induced killer cells: a first-in-human case report. Haematologica (IF 10.1) Pub Date : 2024-05-09 Francesca Elice, Roberta Sommaggio, Elisa Cappuzzello, Marcello Riva, Maria Chiara Tisi, Martina Bernardi, Angela Bozza, Daniela Catanzaro, Katia Chieregato, Anna Merlo, Ilaria Giaretta, Anna Dalla Pieta, Mauro Krampera, Carlo Visco, Livio Trentin, Andrea Visentin, Alberto Tosetto, Giuseppe Astori, Antonio Rosato
Not available.
-
Evaluation of the ATM L2307F germline variant in 121 Italian pedigrees with familial myeloproliferative neoplasms. Haematologica (IF 10.1) Pub Date : 2024-04-24 Oscar Borsani, Roland Jäger, Daniela Pietra, Ines Flieder, Giacomo Riccaboni, Robert Kralovics, Elisa Rumi
Not available.
-
Follicular lymphoma treatment decisions: put GELF on the shelf? Haematologica (IF 10.1) Pub Date : 2024-04-24 Brian K Link
Not available.
-
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens. Haematologica (IF 10.1) Pub Date : 2024-04-24 David Baden, Sven Zukunft, Gema Hernandez, Nadine Wolgast, Sophie Steinhauser, Alexander Pohlmann, Christoph Schliemann, Jan-Henrik Mikesch, Bjorn Steffen, Tim Sauer, Maher Hanoun, Kerstin Schafer-Eckart, Stefan W Krause, Mathias Hanel, Hermann Einsele, Edgar Jost, Tim H Brummendorf, Sebastian Scholl, Andreas Hochhaus, Andreas Neubauer, Andreas Burchert, Martin Kaufmann, Dirk Niemann, Markus Schaich
In newly diagnosed acute myeloid leukemia, immediate initiation of treatment is standard of care. However, deferral of antileukemic therapy may be indicated to assess comorbidities or pre-therapeutic risk factors. We explored the impact of time from diagnosis to treatment on outcomes in newly diagnosed acute myeloid leukemia undergoing venetoclax-based therapy in two distinct cohorts. By querying the
-
Central nervous system prophylaxis: it's time to start from scratch. Haematologica (IF 10.1) Pub Date : 2024-04-24 Diego Villa
Not available.
-
Differential activation of basal and IL-7-induced PI3K/Akt/mTOR and JAK/STAT5 signaling distinguishes pediatric from adult acute lymphoblastic leukemia. Haematologica (IF 10.1) Pub Date : 2024-04-24 Marta B Fernandes, A Margarida Gomes, Mariana L Oliveira, Joana Caldas, Paulo Lúcio, Rathana Kim, Aurélie Caye-Eude, Filomena Pereira, Aida B De Sousa, Alessia De Stefano, Matilde Y Follo, Maria V Soares, João F Lacerda, Joana Desterro, Hélène Cavé, Emmanuelle Clappier, Ximo Duarte, Patrícia Ribeiro, João T Barata
Not available.
-
Monocyte response to SARS-CoV-2 protein ORF8 is associated with severe COVID-19 infection in patients with chronic lymphocytic leukemia. Haematologica (IF 10.1) Pub Date : 2024-04-24 Gordon J Ruan, Xiaosheng Wu, Kimberly A Gwin, Michelle K Manske, Jithma P Abeykoon, Vaishali Bhardwaj, Taylor L Witter, Matthew J Schellenberg, Kari G Rabe, Neil E Kay, Sameer A Parikh, Thomas E Witzig
The open reading frame 8 (ORF8) protein, encoded by the SARS-CoV-2 virus after infection, stimulates monocytes/macrophages to produce pro-inflammatory cytokines. We hypothesized that a positive ex vivo monocyte response to ORF8 protein pre-COVID-19 would be associated with subsequent severe COVID-19. We tested ORF8 ex vivo on peripheral blood mononuclear cells (PBMCs) from 26 anonymous healthy blood
-
Do it once, but do it right. Haematologica (IF 10.1) Pub Date : 2024-04-24 Layal Yasin, Arndt Borkhardt
Not available.
-
Oral iron supplementation: new formulations, old questions. Haematologica (IF 10.1) Pub Date : 2024-04-11 Kostas Pantopoulos
Iron deficiency anemia and pre-anemic iron deficiency are the most frequent pathologies. The first line of treatment involves oral iron supplementation. The simplest, least expensive, and most frequently prescribed drug is ferrous sulfate, while other ferrous salts and ferric complexes with polysaccharides or succinylated milk proteins are also widely used. In recent years, novel iron formulations
-
SH2B3 alterations in a novel genetic condition, juvenile myelomonocytic leukemia, and myeloproliferative neoplasia. Haematologica (IF 10.1) Pub Date : 2024-04-11 Charlotte M Niemeyer, Miriam Erlacher
Not available.
-
Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes. Haematologica (IF 10.1) Pub Date : 2024-04-11 Agata Gruszczynska, Abhishek Maiti, Christopher A Miller, Sai Mukund Ramakrishnan, Daniel C Link, Geoffrey L Uy, Allegra A Petti, Kala Hayes, Courtney D DiNardo, Farhad Ravandi, Timothy J Ley, David H Spencer, Feng Gao, Marina Y Konopleva, John S Welch
Not available.
-
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica (IF 10.1) Pub Date : 2024-04-11 Gregory W Roloff, Satyajit Kosuri, Mariam T Nawas, Adam S DuVall, Anand A Patel, Peter A Riedell, Olatoyosi Odenike, Wendy Stock, Richard A Larson, Michael R Bishop, Emma Nunley, Lucy A Godley, Feighanne Hathaway, Daniela Del Gaudio, Soma Das, Lorraine E Canham, Michael W Drazer
Not available.
-
Stem cell factor and erythropoietin-independent production of cultured reticulocytes. Haematologica (IF 10.1) Pub Date : 2024-04-11 Emmanuel Olivier, Shouping Zhang, Zi Yan, Eric E Bouhassira
Cultured reticulocytes can supplement transfusion needs and offer promise for drug delivery and immune tolerization. They can be produced from induced pluripotent stem cells (iPSCs), but the 45-day culture time and cytokine costs make large-scale production prohibitive. To overcome these limitations, we have generated IPSCs that express constitutive SCF receptor and jak2 adaptor alleles. We show that
-
Unfriendly protein of GATA1 and mechanisms of bone marrow failure. Haematologica (IF 10.1) Pub Date : 2024-04-11 Yigal Dror
Not available.
-
Diagnostic challenges and proposed classification of myeloid neoplasms with overlapping features of thrombocytosis, ring sideroblasts and concurrent del(5q) and SF3B1 mutations. Haematologica (IF 10.1) Pub Date : 2024-04-04 Jyoti Kumar, Natasha E Lewis, Sarina Sherpa, Dory Londono, Xiaotian Sun, Qi Gao, Maria E Arcila, Mikhail Roshal, Yanming Zhang, Wenbin Xiao, Alexander Chan
Not available.
-
Prognostic relevance of tumor-infiltrating CD4+ cells and total metabolic tumor volume-based risk stratification in diffuse large B-cell lymphoma. Haematologica (IF 10.1) Pub Date : 2024-04-04 Daisuke Ikeda, Mitsuaki Oura, Atsushi Uehara, Rikako Tabata, Kentaro Narita, Masami Takeuchi, Youichi Machida, Kosei Matsue
To elucidate the relationship between pre-treatment radiomic parameters and the proportions of various tumour-infiltrating (TI) cells, we retrospectively analysed the association of total metabolic tumour volume (TMTV) and TI cells on biopsied tumour lesions in 171 patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). The surface markers of TI cells were analysed by multicolour flow
-
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry. Haematologica (IF 10.1) Pub Date : 2024-04-04 Tommaso Francesco Aiello, Jon Salmanton-Garcia, Francesco Marchesi, Barbora Weinbergerova, Andreas Glenthoj, Jens Van Praet, Francesca Farina, Julio Davila-Valls, Sonia Martin-Perez, Shaimaa El-Ashwah, Martin Schonlein, Iker Falces-Romero, Jorge Labrador, Uluhan Sili, Caterina Buquicchio, Antonio Vena, Gaetan Plantefeve, Verena Petzer, Monika M Biernat, Tobias Lahmer, Ildefonso Espigado, Jaap Van Doesum
Not available.
-
Rethinking paraneoplastic eosinophilia. Haematologica (IF 10.1) Pub Date : 2024-04-04 Kathrin M Bernt
Not available.
-
Endurance training improves oxygen uptake/demand mismatch, metabolic flexibility and recovery in patients with sickle cell disease. Haematologica (IF 10.1) Pub Date : 2024-04-04 Loïs Mougin, Manon Riccetti, Angèle N Merlet, Pablo Bartolucci, Barnabas Gellen, Léo Blervaque, Thomas D'Humières, Frédéric Galactéros, Chi-An W Emhoff, Léonard Féasson, Laurent A Messonnier
Patients with sickle cell disease (SCD) display lower slope coefficients of the oxygen uptake (V_O2) vs. work rate (W) relationship (delineating an O2 uptake/demand mismatch) and a poor metabolic flexibility. Because endurance training (ET) increases the microvascular network and oxidative enzymes activity including one involved in lipid oxidation, ET might improve the slope coefficient of the V_O2
-
CD9 shapes glucocorticoid sensitivity in pediatric B-cell precursor acute lymphoblastic leukemia. Haematologica (IF 10.1) Pub Date : 2024-04-04 Chi Zhang, Kathy Yuen Yee Chan, Wing Hei Ng, John Tak Kit Cheung, Qiwei Sun, Han Wang, Po Yee Chung, Frankie Wai Tsoi Cheng, Alex Wing Kwan Leung, Xiao-Bing Zhang, Po Yi Lee, Siu Ping Fok, Guanglan Lin, Ellen Ngar Yun Poon, Jian-Hua Feng, Yan-Lai Tang, Xue-Qun Luo, Li-Bin Huang, Wei Kang, Patrick Ming Kuen Tang, Junbin Huang, Chun Chen, Junchao Dong, Ester Mejstrikova, Jiaoyang Cai, Yu Liu, Shuhong
Resistance to glucocorticoids (GCs), the common agents for remission induction in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL), poses a significant therapeutic hurdle. Therefore, dissecting the mechanisms shaping GC resistance could lead to new treatment modalities. Here, we showed that CD9- BCP-ALL cells were preferentially resistant to prednisone and dexamethasone over other
-
Hematopoiesis post anti-CD117 monoclonal antibody treatment in wild-type and Fanconi anemia settings. Haematologica (IF 10.1) Pub Date : 2024-04-04 Morgane Denis, Leah Swartzrock, Hana Willner, Quenton R Bubb, Ethan Haslett, Yan Yi Chan, Anzhi Chen, Mark R Krampf, Agnieszka D Czechowicz
Anti-CD117 monoclonal antibody (mAb) agents have emerged as exciting alternative conditioning strategies to traditional genotoxic irradiation or chemotherapy conditioning for both allogeneic and autologous gene-modified hematopoietic stem cell transplantation. Further, these agents are concurrently being explored in the treatment of mast cell disorders. Despite promising results in animal models and
-
Mutual regulation of CD4+ T cells and intravascular fibrin in infections. Haematologica (IF 10.1) Pub Date : 2024-04-04 Tonina T Mueller, Mona Pilartz, Manovriti Thakur, Torben LangHeinrich, Junfu Luo, Rebecca Block, Jonathan K L Hoeflinger, Sarah Meister, Flavio Karaj, Laura Garcia Perez, Rupert Öllinger, Thomas Engleitner, Jakob Thoss, Michael Voelkl, Claudia Tersteeg, Uwe Koedel, Alexander Zigman Kohlmaier, Daniel Teupser, Malgorzata Wygrecka, Haifeng Ye, Klaus T Preissner, Helena Radbruch, Sefer Elezkurtaj, Matthias
Innate myeloid cells especially neutrophils and their extracellular traps are known to promote intravascular coagulation and thrombosis formation in infections and various other conditions. Innate myeloid cell dependent fibrin formation can support systemic immunity while its dysregulation enhances the severity of infectious diseases. Less is known about the immune mechanisms preventing dysregulation
-
Universal germline genetic testing in patients with hematologic malignancies using DNA isolated from nail clippings. Haematologica (IF 10.1) Pub Date : 2024-04-04 Ozge Ceyhan-Birsoy, Elise Fiala, Satshil Rana, Margaret Sheehan, Jennifer Kennedy, Zarina Yelskaya, Vikas Rai, Yirong Li, Ciyu Yang, Donna Wong, Ivelise Rijo, Jacklyn Casanova, Joshua Somar, Nikita Mehta, Hyeonjin Park, Silvana Ostafi, Kanika Arora, Angelika Padunan, Mark D Ewalt, Umut Aypar, Panieh Terraf, Maksym Misyura, Sofia Haque, Gerald G Behr, Tamanna Haque, Maria Sulis, Mark B Geyer, Christopher
Not available.
-
A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia. Haematologica (IF 10.1) Pub Date : 2024-04-04 Guru Subramanian Guru Murthy, Antoine N Saliba, Aniko Szabo, Alexandra Harrington, Sameem Abedin, Karen Carlson, Laura Michaelis, Lyndsey Runaas, Arielle Baim, Alex Hinman, Sonia Maldonado-Schmidt, Annapoorna Venkatachalam, Karen S Flatten, Kevin L Peterson, Paula A Schneider, Mark Litzow, Scott H Kaufmann, Ehab Atallah
Azacitidine/venetoclax is an active regimen in patients with newly diagnosed AML. However, primary or secondary resistance to azacitidine/venetoclax is an area of unmet need and overexpression of MCL-1 is suggested to be a potential resistance mechanism. Pevonedistat inhibits MCL-1 through activation of NOXA, and pevonedistat/azacitidine has previously shown activity in AML. To assess the tolerability
-
HES6 knockdown in human hematopoietic precursor cells reduces their in vivo engraftment potential and their capacity to differentiate into erythroid cells, B cells, T cells and plasmacytoid dendritic cells. Haematologica (IF 10.1) Pub Date : 2024-04-04 Tamara De Vos, Nicole Oatman, Lena Boehme, Tom Putteman, Imke Velghe, Yana Van Droogenbroeck, Stijn De Munter, Michaela Cesnekova, Filip Van Nieuwerburgh, Bart Vandekerckhove, Jan Philippe, Tom Taghon
Hematopoiesis is driven by molecular mechanisms that induce differentiation and proliferation of hematopoietic stem cells and their progeny. This involves the activity of various transcription factors, such as members of the Hairy/Enhancer of Split (HES) family, and important roles for both HES1 and HES4 have been shown in normal and malignant hematopoiesis. Here, we investigated the role of HES6 in
-
Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes. Haematologica (IF 10.1) Pub Date : 2024-04-04 Christianne Bourlon, Claire Roddie, Tobias Menne, Jane Norman, Maeve O'Reilly, Adam Gibb, Caroline Besley, Sridhar Chaganti, Carlos Gonzalez Arias, Ceri Jones, Abdalla Dikair, Sharon Allen, Frances Seymour, Wendy Osborne, Amrith Mathew, William Townsend, Piers Em Patten, Eleni Thoulouli, Ahmed Abdulgawad, Sanne Lugthart, Robin Sanderson, Amy A Kirkwood, Andrea Kuhnl
Not available.
-
Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma. Haematologica (IF 10.1) Pub Date : 2024-04-04 Umair Munawar, Johanna Theuersbacher, Maximilian J Steinhardt, Xiang Zhou, Seungbin Han, Silvia Nerreter, Cornelia Vogt, Shilpa Kurian, Thorsten Keller, Ann-Katrin Regensburger, Eva Teufel, Julia Mersi, Max Bittrich, Franziska Seifert, Malik S Haider, Leo Rasche, Jost Hillenkamp, Hermann Einsele, Daniel Kampik, K Martin Kortüm, Johannes M Waldschmidt
Belantamab mafodotin (belantamab) is a first-in-class anti-BCMA antibody-drug conjugate approved for the treatment of triple-class refractory multiple myeloma. It provides a unique therapeutic option for patients ineligible for CAR-T and bispecific antibody therapy, and/or patients progressing on anti-CD38 treatment where CAR-T and bispecifics might be kept in reserve. Wider use of the drug can be
-
Clonal CD8+ T-cell expansion is associated with complete response to elranatamab in refractory multiple myeloma. Haematologica (IF 10.1) Pub Date : 2024-03-28 Roman Krzysiek, Samuel Bitoun, Rakiba Belkhir, Salima Hacein-Bey-Abina, Xavier Mariette
Not available.
-
More is not always better, sometimes it is just more. Haematologica (IF 10.1) Pub Date : 2024-03-28 Antonio Salar Silvestre
Not available.
-
Non-tuberculous mycobacterial infections in hematology-oncology: we need to look harder. Haematologica (IF 10.1) Pub Date : 2024-03-28 Steven M Holland
Not available.
-
Prevalence of autoimmune diseases in patients with sickle cell disease: a single center retrospective analysis. Haematologica (IF 10.1) Pub Date : 2024-03-28 Man Wai Tang, Erfan Nur, Charlotte F J Van Tuijn, Bart J Biemond
Not available.
-
BCMA x CD3 T-cell engager in a patient with penta-refractory multiple myeloma and HIV: a clinical and immunological report. Haematologica (IF 10.1) Pub Date : 2024-03-28 Leon Cords, Christoph Schaefers, Abdulaziz Kamili, Christian Hoffmann, Sophia Cichutek, Friedrich Haag, Susanne Polywka, Carsten Bokemeyer, Lisa Leypoldt, Winfried Alsdorf, Julian Schulze Zur Wiesch, Katja C Weisel
Not available.
-
High annualized bleeding rates in pediatric patients with inherited platelet function disorders. Haematologica (IF 10.1) Pub Date : 2024-03-28 Shelly Saini, Song Zhang, Sean Yates, Jessica Garcia, Ruchika Sharma, Joseph Formella, Ravindra Sarode, Ayesha Zia
Not available.
-
Benefit of phlebotomy and low-dose aspirin in the prevention of vascular events in patients with EPOR primary familial polycythemia on the island of New Caledonia. Haematologica (IF 10.1) Pub Date : 2024-03-28 Léa Boulnois, Margot Robles, Nada Maaziz, Bernard Aral, Martin Gauthier, Francis Duchene, Marie-Amélie Goujart, Betty Gardie, François Girodon
Not available.
-
Gut microbiome alterations at acute myeloid leukemia diagnosis are associated with muscle weakness and anorexia. Haematologica (IF 10.1) Pub Date : 2024-03-28 Sarah A Pötgens, Violaine Havelange, Sophie Lecop, Fuyong Li, Audrey M Neyrinck, Florence Bindels, Nathalie Neveux, Jean-Baptiste Demoulin, Ine Moors, Tessa Kerre, Johan Maertens, Jens Walter, Hélène Schoemans, Nathalie M Delzenne, Laure B Bindels
The gut microbiota makes critical contributions to host homeostasis, and its role in the treatment of acute myeloid leukaemia (AML) has attracted attention. We investigated whether the gut microbiome is affected by AML, and whether such changes are associated with cachectic hallmarks. Biological samples and clinical data were collected from 30 antibiotic-free AML patients at diagnosis and matched volunteers
-
Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study. Haematologica (IF 10.1) Pub Date : 2024-03-28 Kai-Ni Shen, Ya-Juan Gao, Long Chang, Lu Zhang, Xin-Xin Cao, Zhuang Tian, Yi-Ning Wang, Dao-Bin Zhou, Jian Li
Not available.
-
Elderly long-term survivors in the Nordic phase II study with first-line maintenance temozolomide for primary central nervous system lymphoma: a 10-year follow-up. Haematologica (IF 10.1) Pub Date : 2024-03-28 Elisa Jacobsen Pulczynski, Mikkel Runason Simonsen, Outi Kuittinen, Unn-Merete Fagerli, Martin Erlanson, Øystein Fluge, Sirpa Leppä, Bjørn Østenstad, Alexander Fosså, Mikael Eriksson, Tarec El-Galaly, Hanne Kuitunen, Karin Papworth, Maria Ljungqvist, Martin B Pedersen, Marjukka Pollari
Not available.
-
MYC overexpression in natural killer cell lymphoma: prognostic and therapeutic implications. Haematologica (IF 10.1) Pub Date : 2024-03-28 Chengfeng Bi, Yuhua Huang, Roshia Ali, Fang Wang, Xia Yang, Alyssa Bouska, Lu Xu, Xinbao Hao, Matthew A Lunning, Wing C Chan, Javeed Iqbal, Dennis D Weisenburger, Julie M Vose, Kai Fu
The current clinical management of Extranodal NK/T-cell lymphoma (ENKTL) primarily depends on conventional chemotherapy and radiotherapy, underscoring the need for innovative therapeutic strategies. This study explores the clinical significance and therapeutic implication of c-MYC (MYC) in ENKTL. Initially, we identified MYC protein overexpression in approximately 75% of cases within a large cohort
-
Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent. Haematologica (IF 10.1) Pub Date : 2024-03-28 Nickolas Steinauer, Kristen McCullough, Aref Al-Kali, Hassan B Alkhateeb, Kebede H Begna, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Torghabeh, Mark R Litzow, William J Hogan, Mithun Shah, Mrinal M Patnaik, Animesh Pardanani, Talha Badar, Hemant Murthy, James Foran, Cecilia Arana Yi, Ayalew Tefferi, Naseema Gangat
Not available.
-
Acute myeloid leukemia with mast cell differentiation is characterized by interstitial mast cells, complex karyotype, TP53 alterations and poor prognosis. Haematologica (IF 10.1) Pub Date : 2024-03-28 Do Hwan Kim, Sa A Wang, Wei Wang, Guilin Tang, Shaoying Li, C Cameron Yin, Pei Lin, Marina Konopleva, M James You, Roberto N Miranda, Xiaoqiong Wang, Qing Wei, L Jeffrey Medeiros, Jie Xu
Not available.
-
Non-myeloma light chain cast nephropathy: a multicenter retrospective study on clinicopathological characteristics. Haematologica (IF 10.1) Pub Date : 2024-03-28 Ana Cristina Martins, Jean-Baptiste Gibier, Charles Ronsin, Christine Kandel-Aznar, Anne Moreau, Marion Chapal, Diogo Francisco, Hamza Sakhi, Julie Oniszczuk, Lorraine Gueguen, Anne Grunenwald, Mathilde Devaux, Alexandre Karras, Virginie Royal, Marion Rabant, Viviane Gnemmi, Jérôme Olagne, Jean-Paul Duong Van Huyen, Pierre Isnard
Not available.
-
Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Haematologica (IF 10.1) Pub Date : 2024-03-28 Laurent Garderet, Luuk Gras, Linda Koster, Liesbeth De Wreede, Rovira Montserrat, Laure Vincent, Roland Fenk, Kamaraj Karunanithi, Dries Deeren, Martin Kaufmann, Jürgen Kuball, Hakan Ozdogu, Maria Jesus Pascual Cascon, Jakob Passweg, Adam Rye, Urpu Salmenniemi, John Snowden, Charlotte Toftmann Hansen, Xavier Leleu, Lauris Gastaud, Joanna Drozd Sokolowska, Kavita Raj, Meral Beksac, Stefan Schönland
There is little long-term outcome data on the efficacy of autologous hematopoietic stem cell transplantation (ASCT) in light chain deposition disease (LCDD). We identified 51 LCDD patients in the EBMT registry who had undergone upfront ASCT between 1995 and 2021. The median serum creatinine was 280 μmol/L and 45% required renal replacement therapy (RRT) at time of transplant. The melphalan dose was
-
Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies. Haematologica (IF 10.1) Pub Date : 2024-03-28 Markus Perl, Konstantin Herfeld, Dennis C Harrer, Matthias Höpting, Marina Schweiger, Ulrich Sterz, Leonard Knödler, Susanne Heimerl, Leo Hansmann, Wolfgang Herr, Hendrik Poeck, Daniel Wolff, Matthias Edinger, Christina Hart, Matthias A Fante
Chimeric antigen receptor (CAR-) T cell therapy causes serious side effects including cytokine release syndrome (CRS). CRS-related coagulopathy is associated with hypofibrinogenemia that is thus far considered the result of disseminated intravascular coagulation (DIC) and liver dysfunction. We investigated incidence and risk factors for hypofibrinogenemia in 41 consecutive adult patients with hematologic
-
Type I Interferons: leukemia's old foe in the limelight again. Haematologica (IF 10.1) Pub Date : 2024-03-21 Anil Kumar, Srividya Swaminathan
Not available.
-
Steroid-free combination of 5-azacytidine and venetoclax for the treatment of multiple myeloma. Haematologica (IF 10.1) Pub Date : 2024-03-21 Lyndsey Flanagan, Aisling Coughlan, Nicola Cosgrove, Andrew Roe, Yu Wang, Stephanie Gilmore, Izabela Drozdz, Claire Comerford, Jeremy Ryan, Emma Minihane, Salma Parvin, Michael O'Dwyer, John Quinn, Philip Murphy, Simon Furney, Siobhan Glavey, Tríona Ní Chonghaile, ,
Multiple Myeloma (MM) is an incurable plasma cell malignancy, that despite an unprecedented increase in overall survival, lacks truly risk-adapted or targeted treatments. A proportion of patients with MM depend on BCL-2 for survival and recently the BCL-2 antagonist venetoclax has shown clinical efficacy and safety in t(11;14) and BCL-2 overexpressing MM. However, only a small proportion of MM patients
-
Systemic diffuse large B-cell lymphoma involving the central nervous system have high rates of defective antigen presentation and immune surveillance. Haematologica (IF 10.1) Pub Date : 2024-03-21 Joel Wight, Piers Blombery, Jennifer Lickiss, Melinda Burgess, Clare Gould, Adrian Minson, Fiona Swain, Muhammed B Sabdia, Maher K Gandhi, Andrew Birchley, Colm Keane, Eliza A Hawkes
Not available.
-
Targeting glycolysis to rescue 2-hydroxyglutarate immunosuppressive effects in dendritic cells and acute myeloid leukemia. Haematologica (IF 10.1) Pub Date : 2024-03-14 Angela Maria Savino, Lucille Stuani
Not available.
-
Low-dose non-steroidal anti-inflammatory drugs: a promising approach for the treatment of symptomatic bone marrow failure in Ghosal hematodiaphyseal dysplasia. Haematologica (IF 10.1) Pub Date : 2024-03-14 Jonathan Bordat, Felipe Suarez, Valérie Cormier-Daire, Regis Peffault De Latour, Jean Soulier, Veronique Meignin, Mathilde Doyard, Lise Larcher, Stephane Vanderbecken, Flore Sicre De Fontbrune
Not available.
-
Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: a systematic review and meta-analysis. Haematologica (IF 10.1) Pub Date : 2024-03-14 Elisabeth R Tolley, Christian Lewinter, Lars M Pedersen, Torsten Holm Nielsen
CNS relapse in patients with diffuse large B-cell lymphoma (DLBCL) carries a dismal prognosis with most clinical guidelines recommending CNS prophylaxis to patients deemed at high risk for CNS relapse. However, results from observational studies investigating the effect of CNS prophylaxis have yielded conflicting results.